

Global Oral Medications for Parkinson's Disease Market Growth 2026-2032

<https://marketpublishers.com/r/G756754BEDC9EN.html>

Date: July 2026

Pages: 130

Price: US\$ 3,660.00 (Single User License)

ID: G756754BEDC9EN

Abstracts

The global Oral Medications for Parkinson's Disease market size is predicted to grow from US\$ million in 2025 to US\$ million in 2032; it is expected to grow at a CAGR of % from 2026 to 2032.

Oral medications are a cornerstone of treatment for Parkinson's disease, a neurodegenerative disorder characterized by motor symptoms such as tremors, stiffness, and impaired movement. These medications are primarily designed to manage symptoms and improve quality of life by addressing the underlying dopamine deficiency in the brain. The most commonly prescribed drug is Levodopa, often combined with Carbidopa, which helps convert Levodopa into dopamine while minimizing side effects. Other oral medications include dopamine agonists that mimic dopamine's effects, MAO-B inhibitors that prevent the breakdown of brain dopamine, COMT inhibitors that prolong Levodopa's effects, and anticholinergics that help control tremors. Amantadine, an antiviral, is also used to manage symptoms and dyskinesia.

United States market for Oral Medications for Parkinson's Disease is estimated to increase from US\$ million in 2025 to US\$ million by 2032, at a CAGR of % from 2026 through 2032.

China market for Oral Medications for Parkinson's Disease is estimated to increase from US\$ million in 2025 to US\$ million by 2032, at a CAGR of % from 2026 through 2032.

Europe market for Oral Medications for Parkinson's Disease is estimated to increase from US\$ million in 2025 to US\$ million by 2032, at a CAGR of % from 2026 through 2032.

Global key Oral Medications for Parkinson's Disease players cover AbbVie, Merck, Boehringer Ingelheim, GlaxoSmithKline, Novartis Pharma, etc. In terms of revenue, the global two largest companies occupied for a share nearly % in 2025.

LP Information, Inc. (LPI) ' newest research report, the "Oral Medications for Parkinson's Disease Industry Forecast" looks at past sales and reviews total world Oral Medications for Parkinson's Disease sales in 2025, providing a comprehensive analysis by region and market sector of projected Oral Medications for Parkinson's Disease sales for 2026 through 2032. With Oral Medications for Parkinson's Disease sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US\$ millions of the world Oral Medications for Parkinson's Disease industry.

This Insight Report provides a comprehensive analysis of the global Oral Medications for Parkinson's Disease landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyzes the strategies of leading global companies with a focus on Oral Medications for Parkinson's Disease portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms' unique position in an accelerating global Oral Medications for Parkinson's Disease market.

This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Oral Medications for Parkinson's Disease and breaks down the forecast by Type, by Application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Oral Medications for Parkinson's Disease.

This report presents a comprehensive overview, market shares, and growth opportunities of Oral Medications for Parkinson's Disease market by product type, application, key manufacturers and key regions and countries.

Segmentation by Type:

L-Dopa Formulations

Dopamine Agonists

Mao-B Inhibitors

COMT Inhibitors

Segmentation by Application:

Under 40 Years Old

40-65 Years Old

Above 65 Years Old

This report also splits the market by region:

Americas

United States

Canada

Mexico

Brazil

APAC

China

Japan

Korea

Southeast Asia

India

Australia

Europe

Germany

France

UK

Italy

Russia

Middle East & Africa

Egypt

South Africa

Israel

Turkey

GCC Countries

The below companies that are profiled have been selected based on inputs gathered from primary experts and analysing the company's coverage, product portfolio, its market penetration.

AbbVie

Merck

Boehringer Ingelheim

GlaxoSmithKline

Novartis Pharma

Supernus Pharmaceuticals

Bausch Health

Newron Pharmaceuticals

Teva Pharmaceutica

Glenmark Pharmaceuticals

Orion Pharma

Neurocrine Biosciences

Kyowa Kirin

UCB

Desitin Arzneimittel

Amneal Pharmaceuticals

Organon Pharma

F.Hoffmann-La Roche

Lundbeck

Stada

Key Questions Addressed in this Report

What is the 10-year outlook for the global Oral Medications for Parkinson's Disease market?

What factors are driving Oral Medications for Parkinson's Disease market

growth, globally and by region?

Which technologies are poised for the fastest growth by market and region?

How do Oral Medications for Parkinson's Disease market opportunities vary by end market size?

How does Oral Medications for Parkinson's Disease break out by Type, by Application?

Contents

1 SCOPE OF THE REPORT

- 1.1 Market Introduction
- 1.2 Years Considered
- 1.3 Research Objectives
- 1.4 Market Research Methodology
- 1.5 Research Process and Data Source
- 1.6 Economic Indicators
- 1.7 Currency Considered
- 1.8 Market Estimation Caveats

2 EXECUTIVE SUMMARY

- 2.1 World Market Overview
 - 2.1.1 Global Oral Medications for Parkinson's Disease Annual Sales 2021-2032
 - 2.1.2 World Current & Future Analysis for Oral Medications for Parkinson's Disease by Geographic Region, 2021, 2025 & 2032
 - 2.1.3 World Current & Future Analysis for Oral Medications for Parkinson's Disease by Country/Region, 2021, 2025 & 2032
- 2.2 Oral Medications for Parkinson's Disease Segment by Type
 - 2.2.1 L-Dopa Formulations
 - 2.2.2 Dopamine Agonists
 - 2.2.3 Mao-B Inhibitors
 - 2.2.4 COMT Inhibitors
 - 2.2.5 Oral Medications for Parkinson's Disease Sales by Type
 - 2.2.5.1 Global Oral Medications for Parkinson's Disease Sales Market Share by Type (2021-2026)
 - 2.2.5.2 Global Oral Medications for Parkinson's Disease Revenue and Market Share by Type (2021-2026)
 - 2.2.5.3 Global Oral Medications for Parkinson's Disease Sale Price by Type (2021-2026)
- 2.3 Oral Medications for Parkinson's Disease Segment by Application
 - 2.3.1 Under 40 Years Old
 - 2.3.2 40-65 Years Old
 - 2.3.3 Above 65 Years Old
 - 2.3.4 Oral Medications for Parkinson's Disease Sales by Application
 - 2.3.4.1 Global Oral Medications for Parkinson's Disease Sale Market Share by

Application (2021-2026)

2.3.4.2 Global Oral Medications for Parkinson's Disease Revenue and Market Share by Application (2021-2026)

2.3.4.3 Global Oral Medications for Parkinson's Disease Sale Price by Application (2021-2026)

3 GLOBAL BY COMPANY

3.1 Global Oral Medications for Parkinson's Disease Breakdown Data by Company

3.1.1 Global Oral Medications for Parkinson's Disease Annual Sales by Company (2021-2026)

3.1.2 Global Oral Medications for Parkinson's Disease Sales Market Share by Company (2021-2026)

3.2 Global Oral Medications for Parkinson's Disease Annual Revenue by Company (2021-2026)

3.2.1 Global Oral Medications for Parkinson's Disease Revenue by Company (2021-2026)

3.2.2 Global Oral Medications for Parkinson's Disease Revenue Market Share by Company (2021-2026)

3.3 Global Oral Medications for Parkinson's Disease Sale Price by Company

3.4 Key Manufacturers Oral Medications for Parkinson's Disease Producing Area Distribution, Sales Area, Product Type

3.4.1 Key Manufacturers Oral Medications for Parkinson's Disease Product Location Distribution

3.4.2 Players Oral Medications for Parkinson's Disease Products Offered

3.5 Market Concentration Rate Analysis

3.5.1 Competition Landscape Analysis

3.5.2 Concentration Ratio (CR3, CR5 and CR10) & (2024-2026)

3.6 New Products and Potential Entrants

3.7 Market M&A Activity & Strategy

4 WORLD HISTORIC REVIEW FOR ORAL MEDICATIONS FOR PARKINSON'S DISEASE BY GEOGRAPHIC REGION

4.1 World Historic Oral Medications for Parkinson's Disease Market Size by Geographic Region (2021-2026)

4.1.1 Global Oral Medications for Parkinson's Disease Annual Sales by Geographic Region (2021-2026)

4.1.2 Global Oral Medications for Parkinson's Disease Annual Revenue by Geographic

Region (2021-2026)

4.2 World Historic Oral Medications for Parkinson's Disease Market Size by Country/Region (2021-2026)

4.2.1 Global Oral Medications for Parkinson's Disease Annual Sales by Country/Region (2021-2026)

4.2.2 Global Oral Medications for Parkinson's Disease Annual Revenue by Country/Region (2021-2026)

4.3 Americas Oral Medications for Parkinson's Disease Sales Growth

4.4 APAC Oral Medications for Parkinson's Disease Sales Growth

4.5 Europe Oral Medications for Parkinson's Disease Sales Growth

4.6 Middle East & Africa Oral Medications for Parkinson's Disease Sales Growth

5 AMERICAS

5.1 Americas Oral Medications for Parkinson's Disease Sales by Country

5.1.1 Americas Oral Medications for Parkinson's Disease Sales by Country (2021-2026)

5.1.2 Americas Oral Medications for Parkinson's Disease Revenue by Country (2021-2026)

5.2 Americas Oral Medications for Parkinson's Disease Sales by Type (2021-2026)

5.3 Americas Oral Medications for Parkinson's Disease Sales by Application (2021-2026)

5.4 United States

5.5 Canada

5.6 Mexico

5.7 Brazil

6 APAC

6.1 APAC Oral Medications for Parkinson's Disease Sales by Region

6.1.1 APAC Oral Medications for Parkinson's Disease Sales by Region (2021-2026)

6.1.2 APAC Oral Medications for Parkinson's Disease Revenue by Region (2021-2026)

6.2 APAC Oral Medications for Parkinson's Disease Sales by Type (2021-2026)

6.3 APAC Oral Medications for Parkinson's Disease Sales by Application (2021-2026)

6.4 China

6.5 Japan

6.6 South Korea

6.7 Southeast Asia

- 6.8 India
- 6.9 Australia
- 6.10 China Taiwan

7 EUROPE

- 7.1 Europe Oral Medications for Parkinson's Disease by Country
 - 7.1.1 Europe Oral Medications for Parkinson's Disease Sales by Country (2021-2026)
 - 7.1.2 Europe Oral Medications for Parkinson's Disease Revenue by Country (2021-2026)
- 7.2 Europe Oral Medications for Parkinson's Disease Sales by Type (2021-2026)
- 7.3 Europe Oral Medications for Parkinson's Disease Sales by Application (2021-2026)
- 7.4 Germany
- 7.5 France
- 7.6 UK
- 7.7 Italy
- 7.8 Russia

8 MIDDLE EAST & AFRICA

- 8.1 Middle East & Africa Oral Medications for Parkinson's Disease by Country
 - 8.1.1 Middle East & Africa Oral Medications for Parkinson's Disease Sales by Country (2021-2026)
 - 8.1.2 Middle East & Africa Oral Medications for Parkinson's Disease Revenue by Country (2021-2026)
- 8.2 Middle East & Africa Oral Medications for Parkinson's Disease Sales by Type (2021-2026)
- 8.3 Middle East & Africa Oral Medications for Parkinson's Disease Sales by Application (2021-2026)
- 8.4 Egypt
- 8.5 South Africa
- 8.6 Israel
- 8.7 Turkey
- 8.8 GCC Countries

9 MARKET DRIVERS, CHALLENGES AND TRENDS

- 9.1 Market Drivers & Growth Opportunities
- 9.2 Market Challenges & Risks

9.3 Industry Trends

10 MANUFACTURING COST STRUCTURE ANALYSIS

10.1 Raw Material and Suppliers

10.2 Manufacturing Cost Structure Analysis of Oral Medications for Parkinson's Disease

10.3 Manufacturing Process Analysis of Oral Medications for Parkinson's Disease

10.4 Industry Chain Structure of Oral Medications for Parkinson's Disease

11 MARKETING, DISTRIBUTORS AND CUSTOMER

11.1 Sales Channel

11.1.1 Direct Channels

11.1.2 Indirect Channels

11.2 Oral Medications for Parkinson's Disease Distributors

11.3 Oral Medications for Parkinson's Disease Customer

12 WORLD FORECAST REVIEW FOR ORAL MEDICATIONS FOR PARKINSON'S DISEASE BY GEOGRAPHIC REGION

12.1 Global Oral Medications for Parkinson's Disease Market Size Forecast by Region

12.1.1 Global Oral Medications for Parkinson's Disease Forecast by Region (2027-2032)

12.1.2 Global Oral Medications for Parkinson's Disease Annual Revenue Forecast by Region (2027-2032)

12.2 Americas Forecast by Country (2027-2032)

12.3 APAC Forecast by Region (2027-2032)

12.4 Europe Forecast by Country (2027-2032)

12.5 Middle East & Africa Forecast by Country (2027-2032)

12.6 Global Oral Medications for Parkinson's Disease Forecast by Type (2027-2032)

12.7 Global Oral Medications for Parkinson's Disease Forecast by Application (2027-2032)

13 KEY PLAYERS ANALYSIS

13.1 AbbVie

13.1.1 AbbVie Company Information

13.1.2 AbbVie Oral Medications for Parkinson's Disease Product Portfolios and Specifications

13.1.3 AbbVie Oral Medications for Parkinson's Disease Sales, Revenue, Price and Gross Margin (2021-2026)

13.1.4 AbbVie Main Business Overview

13.1.5 AbbVie Latest Developments

13.2 Merck

13.2.1 Merck Company Information

13.2.2 Merck Oral Medications for Parkinson's Disease Product Portfolios and Specifications

13.2.3 Merck Oral Medications for Parkinson's Disease Sales, Revenue, Price and Gross Margin (2021-2026)

13.2.4 Merck Main Business Overview

13.2.5 Merck Latest Developments

13.3 Boehringer Ingelheim

13.3.1 Boehringer Ingelheim Company Information

13.3.2 Boehringer Ingelheim Oral Medications for Parkinson's Disease Product Portfolios and Specifications

13.3.3 Boehringer Ingelheim Oral Medications for Parkinson's Disease Sales, Revenue, Price and Gross Margin (2021-2026)

13.3.4 Boehringer Ingelheim Main Business Overview

13.3.5 Boehringer Ingelheim Latest Developments

13.4 GlaxoSmithKline

13.4.1 GlaxoSmithKline Company Information

13.4.2 GlaxoSmithKline Oral Medications for Parkinson's Disease Product Portfolios and Specifications

13.4.3 GlaxoSmithKline Oral Medications for Parkinson's Disease Sales, Revenue, Price and Gross Margin (2021-2026)

13.4.4 GlaxoSmithKline Main Business Overview

13.4.5 GlaxoSmithKline Latest Developments

13.5 Novartis Pharma

13.5.1 Novartis Pharma Company Information

13.5.2 Novartis Pharma Oral Medications for Parkinson's Disease Product Portfolios and Specifications

13.5.3 Novartis Pharma Oral Medications for Parkinson's Disease Sales, Revenue, Price and Gross Margin (2021-2026)

13.5.4 Novartis Pharma Main Business Overview

13.5.5 Novartis Pharma Latest Developments

13.6 Supernus Pharmaceuticals

13.6.1 Supernus Pharmaceuticals Company Information

13.6.2 Supernus Pharmaceuticals Oral Medications for Parkinson's Disease Product

Portfolios and Specifications

13.6.3 Supernus Pharmaceuticals Oral Medications for Parkinson's Disease Sales, Revenue, Price and Gross Margin (2021-2026)

13.6.4 Supernus Pharmaceuticals Main Business Overview

13.6.5 Supernus Pharmaceuticals Latest Developments

13.7 Bausch Health

13.7.1 Bausch Health Company Information

13.7.2 Bausch Health Oral Medications for Parkinson's Disease Product Portfolios and Specifications

13.7.3 Bausch Health Oral Medications for Parkinson's Disease Sales, Revenue, Price and Gross Margin (2021-2026)

13.7.4 Bausch Health Main Business Overview

13.7.5 Bausch Health Latest Developments

13.8 Newron Pharmaceuticals

13.8.1 Newron Pharmaceuticals Company Information

13.8.2 Newron Pharmaceuticals Oral Medications for Parkinson's Disease Product Portfolios and Specifications

13.8.3 Newron Pharmaceuticals Oral Medications for Parkinson's Disease Sales, Revenue, Price and Gross Margin (2021-2026)

13.8.4 Newron Pharmaceuticals Main Business Overview

13.8.5 Newron Pharmaceuticals Latest Developments

13.9 Teva Pharmaceutica

13.9.1 Teva Pharmaceutica Company Information

13.9.2 Teva Pharmaceutica Oral Medications for Parkinson's Disease Product Portfolios and Specifications

13.9.3 Teva Pharmaceutica Oral Medications for Parkinson's Disease Sales, Revenue, Price and Gross Margin (2021-2026)

13.9.4 Teva Pharmaceutica Main Business Overview

13.9.5 Teva Pharmaceutica Latest Developments

13.10 Glenmark Pharmaceuticals

13.10.1 Glenmark Pharmaceuticals Company Information

13.10.2 Glenmark Pharmaceuticals Oral Medications for Parkinson's Disease Product Portfolios and Specifications

13.10.3 Glenmark Pharmaceuticals Oral Medications for Parkinson's Disease Sales, Revenue, Price and Gross Margin (2021-2026)

13.10.4 Glenmark Pharmaceuticals Main Business Overview

13.10.5 Glenmark Pharmaceuticals Latest Developments

13.11 Orion Pharma

13.11.1 Orion Pharma Company Information

13.11.2 Orion Pharma Oral Medications for Parkinson's Disease Product Portfolios and Specifications

13.11.3 Orion Pharma Oral Medications for Parkinson's Disease Sales, Revenue, Price and Gross Margin (2021-2026)

13.11.4 Orion Pharma Main Business Overview

13.11.5 Orion Pharma Latest Developments

13.12 Neurocrine Biosciences

13.12.1 Neurocrine Biosciences Company Information

13.12.2 Neurocrine Biosciences Oral Medications for Parkinson's Disease Product Portfolios and Specifications

13.12.3 Neurocrine Biosciences Oral Medications for Parkinson's Disease Sales, Revenue, Price and Gross Margin (2021-2026)

13.12.4 Neurocrine Biosciences Main Business Overview

13.12.5 Neurocrine Biosciences Latest Developments

13.13 Kyowa Kirin

13.13.1 Kyowa Kirin Company Information

13.13.2 Kyowa Kirin Oral Medications for Parkinson's Disease Product Portfolios and Specifications

13.13.3 Kyowa Kirin Oral Medications for Parkinson's Disease Sales, Revenue, Price and Gross Margin (2021-2026)

13.13.4 Kyowa Kirin Main Business Overview

13.13.5 Kyowa Kirin Latest Developments

13.14 UCB

13.14.1 UCB Company Information

13.14.2 UCB Oral Medications for Parkinson's Disease Product Portfolios and Specifications

13.14.3 UCB Oral Medications for Parkinson's Disease Sales, Revenue, Price and Gross Margin (2021-2026)

13.14.4 UCB Main Business Overview

13.14.5 UCB Latest Developments

13.15 Desitin Arzneimittel

13.15.1 Desitin Arzneimittel Company Information

13.15.2 Desitin Arzneimittel Oral Medications for Parkinson's Disease Product Portfolios and Specifications

13.15.3 Desitin Arzneimittel Oral Medications for Parkinson's Disease Sales, Revenue, Price and Gross Margin (2021-2026)

13.15.4 Desitin Arzneimittel Main Business Overview

13.15.5 Desitin Arzneimittel Latest Developments

13.16 Amneal Pharmaceuticals

- 13.16.1 Amneal Pharmaceuticals Company Information
- 13.16.2 Amneal Pharmaceuticals Oral Medications for Parkinson's Disease Product Portfolios and Specifications
- 13.16.3 Amneal Pharmaceuticals Oral Medications for Parkinson's Disease Sales, Revenue, Price and Gross Margin (2021-2026)
- 13.16.4 Amneal Pharmaceuticals Main Business Overview
- 13.16.5 Amneal Pharmaceuticals Latest Developments
- 13.17 Organon Pharma
 - 13.17.1 Organon Pharma Company Information
 - 13.17.2 Organon Pharma Oral Medications for Parkinson's Disease Product Portfolios and Specifications
 - 13.17.3 Organon Pharma Oral Medications for Parkinson's Disease Sales, Revenue, Price and Gross Margin (2021-2026)
 - 13.17.4 Organon Pharma Main Business Overview
 - 13.17.5 Organon Pharma Latest Developments
- 13.18 F.Hoffmann-La Roche
 - 13.18.1 F.Hoffmann-La Roche Company Information
 - 13.18.2 F.Hoffmann-La Roche Oral Medications for Parkinson's Disease Product Portfolios and Specifications
 - 13.18.3 F.Hoffmann-La Roche Oral Medications for Parkinson's Disease Sales, Revenue, Price and Gross Margin (2021-2026)
 - 13.18.4 F.Hoffmann-La Roche Main Business Overview
 - 13.18.5 F.Hoffmann-La Roche Latest Developments
- 13.19 Lundbeck
 - 13.19.1 Lundbeck Company Information
 - 13.19.2 Lundbeck Oral Medications for Parkinson's Disease Product Portfolios and Specifications
 - 13.19.3 Lundbeck Oral Medications for Parkinson's Disease Sales, Revenue, Price and Gross Margin (2021-2026)
 - 13.19.4 Lundbeck Main Business Overview
 - 13.19.5 Lundbeck Latest Developments
- 13.20 Stada
 - 13.20.1 Stada Company Information
 - 13.20.2 Stada Oral Medications for Parkinson's Disease Product Portfolios and Specifications
 - 13.20.3 Stada Oral Medications for Parkinson's Disease Sales, Revenue, Price and Gross Margin (2021-2026)
 - 13.20.4 Stada Main Business Overview
 - 13.20.5 Stada Latest Developments

14 RESEARCH FINDINGS AND CONCLUSION

List Of Tables

LIST OF TABLES

Table 1. Oral Medications for Parkinson's Disease Annual Sales CAGR by Geographic Region (2021, 2025 & 2032) & (\$ millions)

Table 2. Oral Medications for Parkinson's Disease Annual Sales CAGR by Country/Region (2021, 2025 & 2032) & (\$ millions)

Table 3. Major Players of L-Dopa Formulations

Table 4. Major Players of Dopamine Agonists

Table 5. Major Players of Mao-B Inhibitors

Table 6. Major Players of COMT Inhibitors

Table 7. Global Oral Medications for Parkinson's Disease Sales by Type (2021-2026) & (K Units)

Table 8. Global Oral Medications for Parkinson's Disease Sales Market Share by Type (2021-2026)

Table 9. Global Oral Medications for Parkinson's Disease Revenue by Type (2021-2026) & (\$ million)

Table 10. Global Oral Medications for Parkinson's Disease Revenue Market Share by Type (2021-2026)

Table 11. Global Oral Medications for Parkinson's Disease Sale Price by Type (2021-2026) & (US\$/Unit)

Table 12. Global Oral Medications for Parkinson's Disease Sale by Application (2021-2026) & (K Units)

Table 13. Global Oral Medications for Parkinson's Disease Sale Market Share by Application (2021-2026)

Table 14. Global Oral Medications for Parkinson's Disease Revenue by Application (2021-2026) & (\$ million)

Table 15. Global Oral Medications for Parkinson's Disease Revenue Market Share by Application (2021-2026)

Table 16. Global Oral Medications for Parkinson's Disease Sale Price by Application (2021-2026) & (US\$/Unit)

Table 17. Global Oral Medications for Parkinson's Disease Sales by Company (2021-2026) & (K Units)

Table 18. Global Oral Medications for Parkinson's Disease Sales Market Share by Company (2021-2026)

Table 19. Global Oral Medications for Parkinson's Disease Revenue by Company (2021-2026) & (\$ millions)

Table 20. Global Oral Medications for Parkinson's Disease Revenue Market Share by

Company (2021-2026)

Table 21. Global Oral Medications for Parkinson's Disease Sale Price by Company (2021-2026) & (US\$/Unit)

Table 22. Key Manufacturers Oral Medications for Parkinson's Disease Producing Area Distribution and Sales Area

Table 23. Players Oral Medications for Parkinson's Disease Products Offered

Table 24. Oral Medications for Parkinson's Disease Concentration Ratio (CR3, CR5 and CR10) & (2024-2026)

Table 25. New Products and Potential Entrants

Table 26. Market M&A Activity & Strategy

Table 27. Global Oral Medications for Parkinson's Disease Sales by Geographic Region (2021-2026) & (K Units)

Table 28. Global Oral Medications for Parkinson's Disease Sales Market Share Geographic Region (2021-2026)

Table 29. Global Oral Medications for Parkinson's Disease Revenue by Geographic Region (2021-2026) & (\$ millions)

Table 30. Global Oral Medications for Parkinson's Disease Revenue Market Share by Geographic Region (2021-2026)

Table 31. Global Oral Medications for Parkinson's Disease Sales by Country/Region (2021-2026) & (K Units)

Table 32. Global Oral Medications for Parkinson's Disease Sales Market Share by Country/Region (2021-2026)

Table 33. Global Oral Medications for Parkinson's Disease Revenue by Country/Region (2021-2026) & (\$ millions)

Table 34. Global Oral Medications for Parkinson's Disease Revenue Market Share by Country/Region (2021-2026)

Table 35. Americas Oral Medications for Parkinson's Disease Sales by Country (2021-2026) & (K Units)

Table 36. Americas Oral Medications for Parkinson's Disease Sales Market Share by Country (2021-2026)

Table 37. Americas Oral Medications for Parkinson's Disease Revenue by Country (2021-2026) & (\$ millions)

Table 38. Americas Oral Medications for Parkinson's Disease Sales by Type (2021-2026) & (K Units)

Table 39. Americas Oral Medications for Parkinson's Disease Sales by Application (2021-2026) & (K Units)

Table 40. APAC Oral Medications for Parkinson's Disease Sales by Region (2021-2026) & (K Units)

Table 41. APAC Oral Medications for Parkinson's Disease Sales Market Share by

Region (2021-2026)

Table 42. APAC Oral Medications for Parkinson's Disease Revenue by Region (2021-2026) & (\$ millions)

Table 43. APAC Oral Medications for Parkinson's Disease Sales by Type (2021-2026) & (K Units)

Table 44. APAC Oral Medications for Parkinson's Disease Sales by Application (2021-2026) & (K Units)

Table 45. Europe Oral Medications for Parkinson's Disease Sales by Country (2021-2026) & (K Units)

Table 46. Europe Oral Medications for Parkinson's Disease Revenue by Country (2021-2026) & (\$ millions)

Table 47. Europe Oral Medications for Parkinson's Disease Sales by Type (2021-2026) & (K Units)

Table 48. Europe Oral Medications for Parkinson's Disease Sales by Application (2021-2026) & (K Units)

Table 49. Middle East & Africa Oral Medications for Parkinson's Disease Sales by Country (2021-2026) & (K Units)

Table 50. Middle East & Africa Oral Medications for Parkinson's Disease Revenue Market Share by Country (2021-2026)

Table 51. Middle East & Africa Oral Medications for Parkinson's Disease Sales by Type (2021-2026) & (K Units)

Table 52. Middle East & Africa Oral Medications for Parkinson's Disease Sales by Application (2021-2026) & (K Units)

Table 53. Key Market Drivers & Growth Opportunities of Oral Medications for Parkinson's Disease

Table 54. Key Market Challenges & Risks of Oral Medications for Parkinson's Disease

Table 55. Key Industry Trends of Oral Medications for Parkinson's Disease

Table 56. Oral Medications for Parkinson's Disease Raw Material

Table 57. Key Suppliers of Raw Materials

Table 58. Oral Medications for Parkinson's Disease Distributors List

Table 59. Oral Medications for Parkinson's Disease Customer List

Table 60. Global Oral Medications for Parkinson's Disease Sales Forecast by Region (2027-2032) & (K Units)

Table 61. Global Oral Medications for Parkinson's Disease Revenue Forecast by Region (2027-2032) & (\$ millions)

Table 62. Americas Oral Medications for Parkinson's Disease Sales Forecast by Country (2027-2032) & (K Units)

Table 63. Americas Oral Medications for Parkinson's Disease Annual Revenue Forecast by Country (2027-2032) & (\$ millions)

Table 64. APAC Oral Medications for Parkinson's Disease Sales Forecast by Region (2027-2032) & (K Units)

Table 65. APAC Oral Medications for Parkinson's Disease Annual Revenue Forecast by Region (2027-2032) & (\$ millions)

Table 66. Europe Oral Medications for Parkinson's Disease Sales Forecast by Country (2027-2032) & (K Units)

Table 67. Europe Oral Medications for Parkinson's Disease Revenue Forecast by Country (2027-2032) & (\$ millions)

Table 68. Middle East & Africa Oral Medications for Parkinson's Disease Sales Forecast by Country (2027-2032) & (K Units)

Table 69. Middle East & Africa Oral Medications for Parkinson's Disease Revenue Forecast by Country (2027-2032) & (\$ millions)

Table 70. Global Oral Medications for Parkinson's Disease Sales Forecast by Type (2027-2032) & (K Units)

Table 71. Global Oral Medications for Parkinson's Disease Revenue Forecast by Type (2027-2032) & (\$ millions)

Table 72. Global Oral Medications for Parkinson's Disease Sales Forecast by Application (2027-2032) & (K Units)

Table 73. Global Oral Medications for Parkinson's Disease Revenue Forecast by Application (2027-2032) & (\$ millions)

Table 74. AbbVie Basic Information, Oral Medications for Parkinson's Disease Manufacturing Base, Sales Area and Its Competitors

Table 75. AbbVie Oral Medications for Parkinson's Disease Product Portfolios and Specifications

Table 76. AbbVie Oral Medications for Parkinson's Disease Sales (K Units), Revenue (\$ Million), Price (US\$/Unit) and Gross Margin (2021-2026)

Table 77. AbbVie Main Business

Table 78. AbbVie Latest Developments

Table 79. Merck Basic Information, Oral Medications for Parkinson's Disease Manufacturing Base, Sales Area and Its Competitors

Table 80. Merck Oral Medications for Parkinson's Disease Product Portfolios and Specifications

Table 81. Merck Oral Medications for Parkinson's Disease Sales (K Units), Revenue (\$ Million), Price (US\$/Unit) and Gross Margin (2021-2026)

Table 82. Merck Main Business

Table 83. Merck Latest Developments

Table 84. Boehringer Ingelheim Basic Information, Oral Medications for Parkinson's Disease Manufacturing Base, Sales Area and Its Competitors

Table 85. Boehringer Ingelheim Oral Medications for Parkinson's Disease Product

Portfolios and Specifications

Table 86. Boehringer Ingelheim Oral Medications for Parkinson's Disease Sales (K Units), Revenue (\$ Million), Price (US\$/Unit) and Gross Margin (2021-2026)

Table 87. Boehringer Ingelheim Main Business

Table 88. Boehringer Ingelheim Latest Developments

Table 89. GlaxoSmithKline Basic Information, Oral Medications for Parkinson's Disease Manufacturing Base, Sales Area and Its Competitors

Table 90. GlaxoSmithKline Oral Medications for Parkinson's Disease Product Portfolios and Specifications

Table 91. GlaxoSmithKline Oral Medications for Parkinson's Disease Sales (K Units), Revenue (\$ Million), Price (US\$/Unit) and Gross Margin (2021-2026)

Table 92. GlaxoSmithKline Main Business

Table 93. GlaxoSmithKline Latest Developments

Table 94. Novartis Pharma Basic Information, Oral Medications for Parkinson's Disease Manufacturing Base, Sales Area and Its Competitors

Table 95. Novartis Pharma Oral Medications for Parkinson's Disease Product Portfolios and Specifications

Table 96. Novartis Pharma Oral Medications for Parkinson's Disease Sales (K Units), Revenue (\$ Million), Price (US\$/Unit) and Gross Margin (2021-2026)

Table 97. Novartis Pharma Main Business

Table 98. Novartis Pharma Latest Developments

Table 99. Supernus Pharmaceuticals Basic Information, Oral Medications for Parkinson's Disease Manufacturing Base, Sales Area and Its Competitors

Table 100. Supernus Pharmaceuticals Oral Medications for Parkinson's Disease Product Portfolios and Specifications

Table 101. Supernus Pharmaceuticals Oral Medications for Parkinson's Disease Sales (K Units), Revenue (\$ Million), Price (US\$/Unit) and Gross Margin (2021-2026)

Table 102. Supernus Pharmaceuticals Main Business

Table 103. Supernus Pharmaceuticals Latest Developments

Table 104. Bausch Health Basic Information, Oral Medications for Parkinson's Disease Manufacturing Base, Sales Area and Its Competitors

Table 105. Bausch Health Oral Medications for Parkinson's Disease Product Portfolios and Specifications

Table 106. Bausch Health Oral Medications for Parkinson's Disease Sales (K Units), Revenue (\$ Million), Price (US\$/Unit) and Gross Margin (2021-2026)

Table 107. Bausch Health Main Business

Table 108. Bausch Health Latest Developments

Table 109. Newron Pharmaceuticals Basic Information, Oral Medications for Parkinson's Disease Manufacturing Base, Sales Area and Its Competitors

Table 110. Newron Pharmaceuticals Oral Medications for Parkinson's Disease Product Portfolios and Specifications

Table 111. Newron Pharmaceuticals Oral Medications for Parkinson's Disease Sales (K Units), Revenue (\$ Million), Price (US\$/Unit) and Gross Margin (2021-2026)

Table 112. Newron Pharmaceuticals Main Business

Table 113. Newron Pharmaceuticals Latest Developments

Table 114. Teva Pharmaceutica Basic Information, Oral Medications for Parkinson's Disease Manufacturing Base, Sales Area and Its Competitors

Table 115. Teva Pharmaceutica Oral Medications for Parkinson's Disease Product Portfolios and Specifications

Table 116. Teva Pharmaceutica Oral Medications for Parkinson's Disease Sales (K Units), Revenue (\$ Million), Price (US\$/Unit) and Gross Margin (2021-2026)

Table 117. Teva Pharmaceutica Main Business

Table 118. Teva Pharmaceutica Latest Developments

Table 119. Glenmark Pharmaceuticals Basic Information, Oral Medications for Parkinson's Disease Manufacturing Base, Sales Area and Its Competitors

Table 120. Glenmark Pharmaceuticals Oral Medications for Parkinson's Disease Product Portfolios and Specifications

Table 121. Glenmark Pharmaceuticals Oral Medications for Parkinson's Disease Sales (K Units), Revenue (\$ Million), Price (US\$/Unit) and Gross Margin (2021-2026)

Table 122. Glenmark Pharmaceuticals Main Business

Table 123. Glenmark Pharmaceuticals Latest Developments

Table 124. Orion Pharma Basic Information, Oral Medications for Parkinson's Disease Manufacturing Base, Sales Area and Its Competitors

Table 125. Orion Pharma Oral Medications for Parkinson's Disease Product Portfolios and Specifications

Table 126. Orion Pharma Oral Medications for Parkinson's Disease Sales (K Units), Revenue (\$ Million), Price (US\$/Unit) and Gross Margin (2021-2026)

Table 127. Orion Pharma Main Business

Table 128. Orion Pharma Latest Developments

Table 129. Neurocrine Biosciences Basic Information, Oral Medications for Parkinson's Disease Manufacturing Base, Sales Area and Its Competitors

Table 130. Neurocrine Biosciences Oral Medications for Parkinson's Disease Product Portfolios and Specifications

Table 131. Neurocrine Biosciences Oral Medications for Parkinson's Disease Sales (K Units), Revenue (\$ Million), Price (US\$/Unit) and Gross Margin (2021-2026)

Table 132. Neurocrine Biosciences Main Business

Table 133. Neurocrine Biosciences Latest Developments

Table 134. Kyowa Kirin Basic Information, Oral Medications for Parkinson's Disease

Manufacturing Base, Sales Area and Its Competitors

Table 135. Kyowa Kirin Oral Medications for Parkinson's Disease Product Portfolios and Specifications

Table 136. Kyowa Kirin Oral Medications for Parkinson's Disease Sales (K Units), Revenue (\$ Million), Price (US\$/Unit) and Gross Margin (2021-2026)

Table 137. Kyowa Kirin Main Business

Table 138. Kyowa Kirin Latest Developments

Table 139. UCB Basic Information, Oral Medications for Parkinson's Disease Manufacturing Base, Sales Area and Its Competitors

Table 140. UCB Oral Medications for Parkinson's Disease Product Portfolios and Specifications

Table 141. UCB Oral Medications for Parkinson's Disease Sales (K Units), Revenue (\$ Million), Price (US\$/Unit) and Gross Margin (2021-2026)

Table 142. UCB Main Business

Table 143. UCB Latest Developments

Table 144. Desitin Arzneimittel Basic Information, Oral Medications for Parkinson's Disease Manufacturing Base, Sales Area and Its Competitors

Table 145. Desitin Arzneimittel Oral Medications for Parkinson's Disease Product Portfolios and Specifications

Table 146. Desitin Arzneimittel Oral Medications for Parkinson's Disease Sales (K Units), Revenue (\$ Million), Price (US\$/Unit) and Gross Margin (2021-2026)

Table 147. Desitin Arzneimittel Main Business

Table 148. Desitin Arzneimittel Latest Developments

Table 149. Amneal Pharmaceuticals Basic Information, Oral Medications for Parkinson's Disease Manufacturing Base, Sales Area and Its Competitors

Table 150. Amneal Pharmaceuticals Oral Medications for Parkinson's Disease Product Portfolios and Specifications

Table 151. Amneal Pharmaceuticals Oral Medications for Parkinson's Disease Sales (K Units), Revenue (\$ Million), Price (US\$/Unit) and Gross Margin (2021-2026)

Table 152. Amneal Pharmaceuticals Main Business

Table 153. Amneal Pharmaceuticals Latest Developments

Table 154. Organon Pharma Basic Information, Oral Medications for Parkinson's Disease Manufacturing Base, Sales Area and Its Competitors

Table 155. Organon Pharma Oral Medications for Parkinson's Disease Product Portfolios and Specifications

Table 156. Organon Pharma Oral Medications for Parkinson's Disease Sales (K Units), Revenue (\$ Million), Price (US\$/Unit) and Gross Margin (2021-2026)

Table 157. Organon Pharma Main Business

Table 158. Organon Pharma Latest Developments

Table 159. F.Hoffmann-La Roche Basic Information, Oral Medications for Parkinson's Disease Manufacturing Base, Sales Area and Its Competitors

Table 160. F.Hoffmann-La Roche Oral Medications for Parkinson's Disease Product Portfolios and Specifications

Table 161. F.Hoffmann-La Roche Oral Medications for Parkinson's Disease Sales (K Units), Revenue (\$ Million), Price (US\$/Unit) and Gross Margin (2021-2026)

Table 162. F.Hoffmann-La Roche Main Business

Table 163. F.Hoffmann-La Roche Latest Developments

Table 164. Lundbeck Basic Information, Oral Medications for Parkinson's Disease Manufacturing Base, Sales Area and Its Competitors

Table 165. Lundbeck Oral Medications for Parkinson's Disease Product Portfolios and Specifications

Table 166. Lundbeck Oral Medications for Parkinson's Disease Sales (K Units), Revenue (\$ Million), Price (US\$/Unit) and Gross Margin (2021-2026)

Table 167. Lundbeck Main Business

Table 168. Lundbeck Latest Developments

Table 169. Stada Basic Information, Oral Medications for Parkinson's Disease Manufacturing Base, Sales Area and Its Competitors

Table 170. Stada Oral Medications for Parkinson's Disease Product Portfolios and Specifications

Table 171. Stada Oral Medications for Parkinson's Disease Sales (K Units), Revenue (\$ Million), Price (US\$/Unit) and Gross Margin (2021-2026)

Table 172. Stada Main Business

Table 173. Stada Latest Developments

List Of Figures

LIST OF FIGURES

Figure 1. Picture of Oral Medications for Parkinson's Disease

Figure 2. Oral Medications for Parkinson's Disease Report Years Considered

Figure 3. Research Objectives

Figure 4. Research Methodology

Figure 5. Research Process and Data Source

Figure 6. Global Oral Medications for Parkinson's Disease Sales Growth Rate
2021-2032 (K Units)

Figure 7. Global Oral Medications for Parkinson's Disease Revenue Growth Rate
2021-2032 (\$ millions)

Figure 8. Oral Medications for Parkinson's Disease Sales by Geographic Region (2021,
2025 & 2032) & (\$ millions)

Figure 9. Oral Medications for Parkinson's Disease Sales Market Share by
Country/Region (2025)

Figure 10. Oral Medications for Parkinson's Disease Sales Market Share by
Country/Region (2021, 2025 & 2032)

Figure 11. Product Picture of L-Dopa Formulations

Figure 12. Product Picture of Dopamine Agonists

Figure 13. Product Picture of Mao-B Inhibitors

Figure 14. Product Picture of COMT Inhibitors

Figure 15. Global Oral Medications for Parkinson's Disease Sales Market Share by
Type in 2026

Figure 16. Global Oral Medications for Parkinson's Disease Revenue Market Share by
Type (2021-2026)

Figure 17. Oral Medications for Parkinson's Disease Consumed in Under 40 Years Old

Figure 18. Global Oral Medications for Parkinson's Disease Market: Under 40 Years Old
(2021-2026) & (K Units)

Figure 19. Oral Medications for Parkinson's Disease Consumed in 40-65 Years Old

Figure 20. Global Oral Medications for Parkinson's Disease Market: 40-65 Years Old
(2021-2026) & (K Units)

Figure 21. Oral Medications for Parkinson's Disease Consumed in Above 65 Years Old

Figure 22. Global Oral Medications for Parkinson's Disease Market: Above 65 Years
Old (2021-2026) & (K Units)

Figure 23. Global Oral Medications for Parkinson's Disease Sale Market Share by
Application (2025)

Figure 24. Global Oral Medications for Parkinson's Disease Revenue Market Share by

Application in 2026

Figure 25. Oral Medications for Parkinson's Disease Sales by Company in 2026 (K Units)

Figure 26. Global Oral Medications for Parkinson's Disease Sales Market Share by Company in 2026

Figure 27. Oral Medications for Parkinson's Disease Revenue by Company in 2026 (\$ millions)

Figure 28. Global Oral Medications for Parkinson's Disease Revenue Market Share by Company in 2026

Figure 29. Global Oral Medications for Parkinson's Disease Sales Market Share by Geographic Region (2021-2026)

Figure 30. Global Oral Medications for Parkinson's Disease Revenue Market Share by Geographic Region in 2026

Figure 31. Americas Oral Medications for Parkinson's Disease Sales 2021-2026 (K Units)

Figure 32. Americas Oral Medications for Parkinson's Disease Revenue 2021-2026 (\$ millions)

Figure 33. APAC Oral Medications for Parkinson's Disease Sales 2021-2026 (K Units)

Figure 34. APAC Oral Medications for Parkinson's Disease Revenue 2021-2026 (\$ millions)

Figure 35. Europe Oral Medications for Parkinson's Disease Sales 2021-2026 (K Units)

Figure 36. Europe Oral Medications for Parkinson's Disease Revenue 2021-2026 (\$ millions)

Figure 37. Middle East & Africa Oral Medications for Parkinson's Disease Sales 2021-2026 (K Units)

Figure 38. Middle East & Africa Oral Medications for Parkinson's Disease Revenue 2021-2026 (\$ millions)

Figure 39. Americas Oral Medications for Parkinson's Disease Sales Market Share by Country in 2026

Figure 40. Americas Oral Medications for Parkinson's Disease Revenue Market Share by Country (2021-2026)

Figure 41. Americas Oral Medications for Parkinson's Disease Sales Market Share by Type (2021-2026)

Figure 42. Americas Oral Medications for Parkinson's Disease Sales Market Share by Application (2021-2026)

Figure 43. United States Oral Medications for Parkinson's Disease Revenue Growth 2021-2026 (\$ millions)

Figure 44. Canada Oral Medications for Parkinson's Disease Revenue Growth 2021-2026 (\$ millions)

Figure 45. Mexico Oral Medications for Parkinson's Disease Revenue Growth 2021-2026 (\$ millions)

Figure 46. Brazil Oral Medications for Parkinson's Disease Revenue Growth 2021-2026 (\$ millions)

Figure 47. APAC Oral Medications for Parkinson's Disease Sales Market Share by Region in 2026

Figure 48. APAC Oral Medications for Parkinson's Disease Revenue Market Share by Region (2021-2026)

Figure 49. APAC Oral Medications for Parkinson's Disease Sales Market Share by Type (2021-2026)

Figure 50. APAC Oral Medications for Parkinson's Disease Sales Market Share by Application (2021-2026)

Figure 51. China Oral Medications for Parkinson's Disease Revenue Growth 2021-2026 (\$ millions)

Figure 52. Japan Oral Medications for Parkinson's Disease Revenue Growth 2021-2026 (\$ millions)

Figure 53. South Korea Oral Medications for Parkinson's Disease Revenue Growth 2021-2026 (\$ millions)

Figure 54. Southeast Asia Oral Medications for Parkinson's Disease Revenue Growth 2021-2026 (\$ millions)

Figure 55. India Oral Medications for Parkinson's Disease Revenue Growth 2021-2026 (\$ millions)

Figure 56. Australia Oral Medications for Parkinson's Disease Revenue Growth 2021-2026 (\$ millions)

Figure 57. China Taiwan Oral Medications for Parkinson's Disease Revenue Growth 2021-2026 (\$ millions)

Figure 58. Europe Oral Medications for Parkinson's Disease Sales Market Share by Country in 2026

Figure 59. Europe Oral Medications for Parkinson's Disease Revenue Market Share by Country (2021-2026)

Figure 60. Europe Oral Medications for Parkinson's Disease Sales Market Share by Type (2021-2026)

Figure 61. Europe Oral Medications for Parkinson's Disease Sales Market Share by Application (2021-2026)

Figure 62. Germany Oral Medications for Parkinson's Disease Revenue Growth 2021-2026 (\$ millions)

Figure 63. France Oral Medications for Parkinson's Disease Revenue Growth 2021-2026 (\$ millions)

Figure 64. UK Oral Medications for Parkinson's Disease Revenue Growth 2021-2026 (\$ millions)

millions)

Figure 65. Italy Oral Medications for Parkinson's Disease Revenue Growth 2021-2026 (\$ millions)

Figure 66. Russia Oral Medications for Parkinson's Disease Revenue Growth 2021-2026 (\$ millions)

Figure 67. Middle East & Africa Oral Medications for Parkinson's Disease Sales Market Share by Country (2021-2026)

Figure 68. Middle East & Africa Oral Medications for Parkinson's Disease Sales Market Share by Type (2021-2026)

Figure 69. Middle East & Africa Oral Medications for Parkinson's Disease Sales Market Share by Application (2021-2026)

Figure 70. Egypt Oral Medications for Parkinson's Disease Revenue Growth 2021-2026 (\$ millions)

Figure 71. South Africa Oral Medications for Parkinson's Disease Revenue Growth 2021-2026 (\$ millions)

Figure 72. Israel Oral Medications for Parkinson's Disease Revenue Growth 2021-2026 (\$ millions)

Figure 73. Turkey Oral Medications for Parkinson's Disease Revenue Growth 2021-2026 (\$ millions)

Figure 74. GCC Countries Oral Medications for Parkinson's Disease Revenue Growth 2021-2026 (\$ millions)

Figure 75. Manufacturing Cost Structure Analysis of Oral Medications for Parkinson's Disease in 2026

Figure 76. Manufacturing Process Analysis of Oral Medications for Parkinson's Disease

Figure 77. Industry Chain Structure of Oral Medications for Parkinson's Disease

Figure 78. Channels of Distribution

Figure 79. Global Oral Medications for Parkinson's Disease Sales Market Forecast by Region (2027-2032)

Figure 80. Global Oral Medications for Parkinson's Disease Revenue Market Share Forecast by Region (2027-2032)

Figure 81. Global Oral Medications for Parkinson's Disease Sales Market Share Forecast by Type (2027-2032)

Figure 82. Global Oral Medications for Parkinson's Disease Revenue Market Share Forecast by Type (2027-2032)

Figure 83. Global Oral Medications for Parkinson's Disease Sales Market Share Forecast by Application (2027-2032)

Figure 84. Global Oral Medications for Parkinson's Disease Revenue Market Share Forecast by Application (2027-2032)

I would like to order

Product name: Global Oral Medications for Parkinson's Disease Market Growth 2026-2032

Product link: <https://marketpublishers.com/r/G756754BEDC9EN.html>

Price: US\$ 3,660.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/G756754BEDC9EN.html>